CITF Research Results

CITF Research Results2022-09-28T09:22:35-04:00

Profiling a cohort of retail workers in Quebec to study the COVID-19 immune response

A CITF-funded team studied the risk to grocery store, hardware store, bar, and restaurant workers during the COVID-19 pandemic. This cohort profile preprint article, not yet peer-reviewed, describes participant demographic, socioeconomic, behavioural, clinical, and occupational characteristics, as well as whether participants tested positive for SARS-CoV-2, experienced any COVID-19 symptoms (where applicable), and were vaccinated.

October 2, 2023|Occupational groups|

Hybrid immunity conferred stronger immune responses in children and adults than vaccination alone

A CITF-supported study, published in preprint and not yet peer-reviewed, found that two doses of mRNA vaccine (Pfizer or Moderna) produce robust antibody responses three months post-vaccination in both children and adults. Additionally, hybrid immunity (immunity derived from the combination of SARS-CoV-2 infection and vaccination) conferred stronger immune responses in both age groups when compared to vaccination alone.

October 2, 2023|Immune science|

Healthcare workers had higher incidences of SARS-CoV-2 infection and mental health conditions compared to the general population

A CITF-funded study, published in preprint and not yet peer-reviewed, found that healthcare workers (HCW) in Alberta had a higher incidence of SARS-CoV-2 infection and of mental health issues compared to community members (referents) seen in pre-pandemic physician consultations who were matched on gender, age, and geographic location. Excess infection was most notable early in the pandemic and during the fifth (Omicron) wave.

October 2, 2023|Healthcare workers|

Each booster dose increases vaccine effectiveness against all Omicron subvariants

A CITF-funded study, published in preprint and not yet peer-reviewed, provided evidence that individuals with hybrid immunity (a combination of infection-acquired and vaccine-induced SARS-CoV-2 immunity) had nearly 90% protection against severe outcomes (hospitalization or death) during the Omicron BA.1/BA.2 and BA.4/BA.5 predominant periods.

October 2, 2023|Vaccine surveillance|
Go to Top